

# Laura Fouassier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/659106/publications.pdf>

Version: 2024-02-01

65  
papers

5,026  
citations

126907

33  
h-index

138484

58  
g-index

68  
all docs

68  
docs citations

68  
times ranked

6326  
citing authors

#	ARTICLE	IF	CITATIONS
1	Self-Assembled Fe <sub>3</sub> O <sub>4</sub> Nanocrystals: Toward Nanoscale Precision of Photothermal Effects in the Tumor Microenvironment. <i>Advanced Functional Materials</i> , 2021, 31, 2006824.	14.9	35
2	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 377-388.	4.1	5
3	Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche. <i>Journal of Hepatology</i> , 2021, 74, 771-774.	3.7	2
4	Cholangiopathy aggravation is caused by VDR ablation and alleviated by VDR-independent vitamin D signaling in ABCB4 knockout mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166067.	3.8	9
5	Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. <i>ELife</i> , 2021, 10, .	6.0	127
6	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	20
7	Zinc Finger Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor Stroma Paracrine Signaling. <i>Hepatology</i> , 2021, 74, 3194-3212.	7.3	20
8	Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 627-635.	3.7	84
9	Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment. <i>Journal of Hepatology</i> , 2020, 73, 1007-1009.	3.7	9
10	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	17.8	1,155
11	Cancer-associated fibroblasts in cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 63-69.	2.3	43
12	Photothermal Depletion of Cancer-Associated Fibroblasts Normalizes Tumor Stiffness in Desmoplastic Cholangiocarcinoma. <i>ACS Nano</i> , 2020, 14, 5738-5753.	14.6	54
13	Cold-Atmospheric Plasma Induces Tumor Cell Death in Preclinical In Vivo and In Vitro Models of Human Cholangiocarcinoma. <i>Cancers</i> , 2020, 12, 1280.	3.7	43
14	THU-502-ZEB1 expression in myfibroblasts regulates their interaction with cholangiocarcinoma cells promoting tumour progression. <i>Journal of Hepatology</i> , 2019, 70, e381.	3.7	0
15	Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. <i>Liver International</i> , 2019, 39, 43-62.	3.9	54
16	Atmospheric pressure plasma jets applied to cancerology: correlating electrical configuration with in vivo toxicity and therapeutic efficiency. <i>Journal Physics D: Applied Physics</i> , 2019, 52, 245201.	2.8	20
17	Insulin receptor isoform A favors tumor progression in human hepatocellular carcinoma by increasing stem/progenitor cell features. <i>Cancer Letters</i> , 2019, 450, 155-168.	7.2	12
18	The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 4282-4296.	7.0	68

#	ARTICLE	IF	CITATIONS
19	Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology. <i>Hepatology</i> , 2018, 67, 762-773.	7.3	48
20	Insulin receptor isoform A is a new player in the progression of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, S666-S667.	3.7	0
21	Unveiling resistance mechanisms to EGFR inhibitors in cholangiocarcinoma. <i>Oncotarget</i> , 2018, 9, 37274-37275.	1.8	6
22	Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance. <i>Oncogene</i> , 2017, 36, 3067-3079.	5.9	69
23	Overcoming the tumor microenvironment: the role of nanohyperthermia. <i>Nanomedicine</i> , 2017, 12, 1213-1215.	3.3	7
24	Insulin/IGF-1 receptors mediate acquired resistance to anti-EGFR therapy in human cholangiocarcinoma cells. <i>Journal of Hepatology</i> , 2017, 66, S463.	3.7	0
25	Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks. <i>Journal of Hepatology</i> , 2017, 66, 424-441.	3.7	115
26	A PDZ-Like Motif in the Biliary Transporter ABCB4 Interacts with the Scaffold Protein EBP50 and Regulates ABCB4 Cell Surface Expression. <i>PLoS ONE</i> , 2016, 11, e0146962.	2.5	9
27	Loss of ezrin in human intrahepatic cholangiocarcinoma is associated with ectopic expression of E-cadherin. <i>Histopathology</i> , 2016, 69, 211-221.	2.9	4
28	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 261-280.	17.8	964
29	Insulin/insulin-like growth factor-1 receptors mediate acquired resistance to anti-EGFR therapy in human cholangiocarcinoma cells by regulating an epithelial to mesenchymal transition/cancer stem cell axis. <i>European Journal of Cancer</i> , 2016, 61, S131.	2.8	0
30	Rac1 and EMT: a dangerous liaison?. <i>Translational Cancer Research</i> , 2016, 5, S1483-S1485.	1.0	1
31	Ezrin finds its groove in cholangiocytes. <i>Hepatology</i> , 2015, 61, 1467-1470.	7.3	5
32	E-cadherin, guardian of liver physiology. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 3-6.	1.5	18
33	Mitogen-activated protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-induced oxidative stress in human hepatobiliary cancer cells. <i>Free Radical Biology and Medicine</i> , 2015, 89, 34-46.	2.9	20
34	Mechanical induction of the tumorigenic $\beta$ -catenin pathway by tumour growth pressure. <i>Nature</i> , 2015, 523, 92-95.	27.8	288
35	P48 EGF/EGFR AXIS CONTRIBUTES TO THE PROGRESSION OF CHOLANGIOCARCINOMA THROUGH THE INDUCTION OF AN EPITHELIAL-MESENCHYMAL TRANSITION. <i>Journal of Hepatology</i> , 2014, 60, S83.	3.7	1
36	EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. <i>Journal of Hepatology</i> , 2014, 61, 325-332.	3.7	101

#	ARTICLE	IF	CITATIONS
37	Immunohistochemical profile of ezrin and radixin in human liver epithelia during fetal development and pediatric cholestatic diseases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 142-151.	1.5	9
38	Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. <i>Hepatology</i> , 2013, 58, 2001-2011.	7.3	85
39	Loss of EBP50 stimulates EGFR activity to induce EMT phenotypic features in biliary cancer cells. <i>Oncogene</i> , 2012, 31, 1376-1388.	5.9	50
40	Roles of the scaffolding proteins NHERF in liver biology. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 176-181.	1.5	17
41	40 EBP50, A PDZ-CONTAINING PROTEIN, REGULATES EGFR-INDUCED CELL SCATTERING AND MIGRATION IN HUMAN CANCER BILIARY EPITHELIAL CELLS. <i>Journal of Hepatology</i> , 2010, 52, S18.	3.7	1
42	Bile Salts Control the Antimicrobial Peptide Cathelicidin Through Nuclear Receptors in the Human Biliary Epithelium. <i>Gastroenterology</i> , 2009, 136, 1435-1443.	1.3	199
43	Ezrin-Radixin-Moesin-Binding Phosphoprotein (EBP50), an Estrogen-Inducible Scaffold Protein, Contributes to Biliary Epithelial Cell Proliferation. <i>American Journal of Pathology</i> , 2009, 174, 869-880.	3.8	40
44	Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. , 2009, , 86-94.		0
45	Hypoxia-induced changes in the expression of rat hepatobiliary transporter genes. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G25-G35.	3.4	54
46	311 Regulation of hepatobiliary transporters in response to hypoxia. <i>Journal of Hepatology</i> , 2006, 44, S120-S121.	3.7	0
47	312 EBP50, a scaffold protein participating in the proliferation of cholangiocytes, is delocalized in the ductular reaction associated with cystic fibrosis liver disease. <i>Journal of Hepatology</i> , 2006, 44, S121.	3.7	0
48	Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation. <i>Hepatology</i> , 2006, 43, 1125-1134.	7.3	66
49	Protein kinase C regulates the phosphorylation and oligomerization of ERM binding phosphoprotein 50. <i>Experimental Cell Research</i> , 2005, 306, 264-273.	2.6	35
50	Adaptative bile duct proliferative response in experimental bile duct ischemia. <i>Journal of Hepatology</i> , 2005, 42, 257-265.	3.7	57
51	Characterization of an ankyrin repeat-containing Shank2 isoform (Shank2E) in liver epithelial cells. <i>Biochemical Journal</i> , 2004, 380, 181-191.	3.7	43
52	Emerging Roles of the Actin Cytoskeleton in Cholangiocyte Function and Disease. <i>Seminars in Liver Disease</i> , 2002, 22, 263-276.	3.6	14
53	Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. <i>Journal of Hepatology</i> , 2002, 37, 184-191.	3.7	82
54	Cholangiocytes exhibit dynamic, actin-dependent apical membrane turnover. <i>American Journal of Physiology - Cell Physiology</i> , 2002, 282, C1042-C1052.	4.6	32

#	ARTICLE	IF	CITATIONS
55	The endothelin receptor antagonist bosentan modifies canalicular bile secretion. <i>Journal of Hepatology</i> , 2001, 34, 189.	3.7	0
56	Ezrin-radixin-moesin-binding phosphoprotein 50 is expressed at the apical membrane of rat liver epithelia. <i>Hepatology</i> , 2001, 33, 166-176.	7.3	98
57	ATP depletion in rat cholangiocytes leads to marked internalization of membrane proteins. <i>Hepatology</i> , 2000, 31, 1045-1054.	7.3	36
58	Evidence for Ezrin-Radixin-Moesin-binding Phosphoprotein 50 (EBP50) Self-association through PDZ-PDZ Interactions. <i>Journal of Biological Chemistry</i> , 2000, 275, 25039-25045.	3.4	105
59	Vascular Endothelin-1 Gene Expression and Synthesis and Effect on Renal Type I Collagen Synthesis and Nephroangiosclerosis During Nitric Oxide Synthase Inhibition in Rats. <i>Circulation</i> , 1999, 99, 2185-2191.	1.6	83
60	Regulation of electrogenic anion secretion in normal and cystic fibrosis gallbladder mucosa. <i>Hepatology</i> , 1999, 29, 5-13.	7.3	42
61	Endothelium-dependent blunted membrane potential responses to ATP-sensitive K <sup>+</sup> channel modulators in aortae from rats with cirrhosis. <i>Journal of Hepatology</i> , 1999, 30, 107-114.	3.7	9
62	Cellular localization of endothelin-1 and increased production in liver injury in the rat: Potential for autocrine and paracrine effects on stellate cells. <i>Hepatology</i> , 1998, 27, 472-480.	7.3	209
63	Endothelin-1 is synthesized and inhibits cyclic adenosine monophosphate- dependent anion secretion by an autocrine/paracrine mechanism in gallbladder epithelial cells.. <i>Journal of Clinical Investigation</i> , 1998, 101, 2881-2888.	8.2	36
64	Growth inhibitory properties of endothelin-1 in activated human hepatic stellate cells: a cyclic adenosine monophosphate-mediated pathway. Inhibition of both extracellular signal-regulated kinase and c-Jun kinase and upregulation of endothelin B receptors.. <i>Journal of Clinical Investigation</i> , 1996, 98, 2771-2778.	8.2	97
65	Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells. An endothelin B receptor-mediated pathway.. <i>Journal of Clinical Investigation</i> , 1995, 96, 42-49.	8.2	102